Ayala Pharmaceuticals (ADXS) Competitors $0.03 -0.02 (-34.71%) As of 03:16 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock ADXS vs. MTNB, SNOA, ADXN, PRTG, CELZ, CSCI, AEON, MYNZ, TSBX, and CLRBShould you be buying Ayala Pharmaceuticals stock or one of its competitors? The main competitors of Ayala Pharmaceuticals include Matinas Biopharma (MTNB), Sonoma Pharmaceuticals (SNOA), Addex Therapeutics (ADXN), Portage Biotech (PRTG), Creative Medical Technology (CELZ), COSCIENS Biopharma (CSCI), AEON Biopharma (AEON), Mainz Biomed (MYNZ), Turnstone Biologics (TSBX), and Cellectar Biosciences (CLRB). These companies are all part of the "pharmaceutical products" industry. Ayala Pharmaceuticals vs. Its Competitors Matinas Biopharma Sonoma Pharmaceuticals Addex Therapeutics Portage Biotech Creative Medical Technology COSCIENS Biopharma AEON Biopharma Mainz Biomed Turnstone Biologics Cellectar Biosciences Ayala Pharmaceuticals (NASDAQ:ADXS) and Matinas Biopharma (NYSE:MTNB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation. Does the media refer more to ADXS or MTNB? In the previous week, Ayala Pharmaceuticals' average media sentiment score of 0.00 equaled Matinas Biopharma'saverage media sentiment score. Company Overall Sentiment Ayala Pharmaceuticals Neutral Matinas Biopharma Neutral Do insiders & institutionals have more ownership in ADXS or MTNB? 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.8% of Matinas Biopharma shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Matinas Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, ADXS or MTNB? Ayala Pharmaceuticals has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Matinas Biopharma has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500. Do analysts prefer ADXS or MTNB? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is ADXS or MTNB more profitable? Ayala Pharmaceuticals' return on equity of 0.00% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Ayala PharmaceuticalsN/A N/A N/A Matinas Biopharma N/A -123.06%-94.28% Which has preferable valuation & earnings, ADXS or MTNB? Matinas Biopharma has lower revenue, but higher earnings than Ayala Pharmaceuticals. Matinas Biopharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAyala Pharmaceuticals$3.24M0.44-$48.07M-$7.980.00Matinas BiopharmaN/AN/A-$22.94M-$3.89-0.51 SummaryMatinas Biopharma beats Ayala Pharmaceuticals on 6 of the 10 factors compared between the two stocks. Get Ayala Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXS vs. The Competition Export to ExcelMetricAyala PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.42M$848.86M$5.74B$9.78BDividend YieldN/A4.84%4.40%4.04%P/E Ratio0.001.1531.5526.39Price / Sales0.44138.82382.8986.63Price / CashN/A19.5637.7259.11Price / Book-0.026.7710.106.62Net Income-$48.07M-$4.20M$3.26B$265.42M7 Day PerformanceN/A3.73%3.58%3.45%1 Month PerformanceN/A2.32%3.69%0.45%1 Year PerformanceN/A15.85%37.69%19.41% Ayala Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXSAyala PharmaceuticalsN/A$0.03-34.7%N/A+66.5%$1.42M$3.24M0.0020Gap DownMTNBMatinas Biopharma0.6337 of 5 stars$1.70-0.6%N/AN/A$8.65MN/A-0.3530SNOASonoma PharmaceuticalsN/A$5.23-2.2%N/A+1,952.8%$8.59M$14.91M-2.13180Gap DownADXNAddex Therapeutics2.7036 of 5 stars$8.11+0.2%$30.00+270.1%+3.5%$8.59M$460K-23.8430Upcoming EarningsPRTGPortage Biotech1.0184 of 5 stars$8.00-5.5%N/A+22.3%$8.40MN/A-0.196Gap DownCELZCreative Medical Technology1.2519 of 5 stars$3.23-1.8%N/A-5.8%$8.33M$6K-1.025CSCICOSCIENS BiopharmaN/A$2.63-9.0%N/AN/A$8.28M$9.59M-0.4420Positive NewsGap UpAEONAEON Biopharma2.9841 of 5 stars$0.73-3.2%$360.00+49,147.6%-98.9%$8.26MN/A4.065Gap DownMYNZMainz Biomed3.0198 of 5 stars$1.80flat$14.00+677.8%-90.5%$8.24M$890K-0.0330Gap UpTSBXTurnstone Biologics3.0883 of 5 stars$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782CLRBCellectar Biosciences2.4205 of 5 stars$4.50-4.3%$375.00+8,233.3%-92.7%$8.15MN/A-0.2310News CoveragePositive News Related Companies and Tools Related Companies Matinas Biopharma Alternatives Sonoma Pharmaceuticals Alternatives Addex Therapeutics Alternatives Portage Biotech Alternatives Creative Medical Technology Alternatives COSCIENS Biopharma Alternatives AEON Biopharma Alternatives Mainz Biomed Alternatives Turnstone Biologics Alternatives Cellectar Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXS) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access